3692.HK
Hansoh Pharmaceutical Group Company Limited

Healthcare · Drug Manufacturers - Specialty & Generic · valued as of 2026-11-03 · statements 2025-12-31

Average Intrinsic Value

11.33B USD

Market Cap

26.42B USD

Margin of Safety

-133.3%

Intrinsic / Market Ratio

0.43×

Projections, not exact values. Intrinsic Values are projected from each company's past reports. They show which stocks look cheap compared with the others, not exactly what a stock is worth.

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

EPV + Growth

14.11B USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

11.43B USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

8.44B USD

15 years of cash for shareholders and lenders, less what is owed

Intrinsic Value

11.33B USD

the plain average of the three, uncapped, as the screener averages them

Intrinsic Value

11.33B USD

from the sum above

Market Cap

26.42B USD

the price on the date above times the shares

Intrinsic Value ÷ Market Cap

0.43×

the ratio the screener ranks by; Margin of Safety -133.3% (1 − Market Cap ÷ Intrinsic Value)

Each card below builds one of the three values from the reported years.

Earnings power value plus growth: 14.11B USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)7.52B USD
+②Net Cash Today4.50B USD
+③Growth Value2.08B USD
=Value14.11B USD

EPV of the Operations (NOPAT over WACC)

7.52B USD

Net cash today

+4.50B USD

Growth Value

+2.08B USD

Value

14.11B USD

①EPV (earnings power value)

7.52B USD

②Net Cash Today

4.50B USD

③Growth Value

2.08B USD

Market value

Market Cap26.42B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-87.3%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 11.43B USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE6.90B USD
+②Equity at Year 15, Today4.52B USD
=Value11.43B USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

6.90B USD

②Equity at Year 15, Today

4.52B USD

Market value

Market Cap26.42B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-131.2%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 8.44B USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).
①Present Value of the 15 Years of FCFF3.71B USD
+②Invested Capital at Year 15, Today230.51M USD
+③Net Cash Today4.50B USD
=Value8.44B USD
FCFF: the NOPAT left for the shareholders and the lenders once the business reinvests what next year's growth needsReinvestment: the part of the year's NOPAT put back into the business to grow the next year; below zero, capital the business releasesPresent value of the FCFFColoured bars show the FCFF, grey bars the reinvestment. With a positive reinvestment the two stacked are the year's NOPAT; with a negative one the grey is below zero, capital the business releases, and the NOPAT is the FCFF plus that negative amount. Shaded, years 6 to 10: the growth rising to its long-run rate and the ROIC on new investment falling to the WACC. Axes linear.

①Present Value of the 15 Years of FCFF

3.71B USD

②Invested Capital at Year 15, Today

230.51M USD

③Net Cash Today

4.50B USD

Market value

Market Cap26.42B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-213.0%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 7.87%
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.56×Market Risk Premium 6.00%= 7.88%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 142.38M USDPretax Income 937.26M USD= 15.19%

The tax the interest saves.

Interest Expense =EBIT 937.71M USD−Pretax Income 937.26M USD= 452.42K USD

The interest the company paid: EBIT is the profit before tax plus the interest.

Cost of Debt =Interest Expense 452.42K USDTotal Debt 15.04M USD×(1 − Tax Rate for WACC 15.19%)= 2.55%

What the lenders are paid a year after the tax the interest saves.

Debt Weight =Total Debt 15.04M USDMarket Cap + Total Debt 26.42B USD + 15.04M USD= 0.06%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 99.94%×Cost of Equity 7.88%+Debt Weight 0.06%×Cost of Debt 2.55%= 7.87%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2025-12-31.

Total Assets 5.71B USD − Total Liabilities 649.00M USD = Book Value Today 5.06B USD

Total Debt 15.04M USD − Cash and Short-Term Investments 4.52B USD = Net Debt Today -4.50B USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 12.2%at most 5%passes6,053,955,423 / 5,923,735,370
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets3.0%at least -10.0%passes(964.11M USD − 794.87M USD) ÷ 5.71B USD
Price to bookMarket Cap ÷ Book Value Today5.22×at most 3×does not pass26.42B USD ÷ 5.06B USD
Operating marginOperating Income ÷ Revenue36.9%above 10.0%passes793.66M USD ÷ 2.15B USD
Revenue growthRevenue ÷ Revenue a Year Before − 127.9%above 10.0%passes2.15B USD / 1.68B USD
Net cash(Cash − Total Debt) ÷ Market Cap17.0%above -30%passes(4.51B USD − 15.04M USD) ÷ 26.42B USD
Operating efficiencyOperating Income ÷ Gross Profit41.0%above 25.0%passes793.66M USD ÷ 1.94B USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Share price

34.17 HKD

Enterprise value

174.01B HKD

the provider's own figure

EV / EBITDA

27.62×

Price / book

4.69×

the provider's book

Price / earnings

26.47×

Return on equity

19.4%

the provider's figure, not this page's

Profit margin

42.0%

Revenue growth

11.7%

Analyst target, mean

47.84 HKD

Analysts

24

opinions in the consensus

Financial Statements

The annual lines the screener holds, year by year, in USD at each period's rate; the figures this valuation read are in its calculation above.

USD2022202320242025
Income statement

Revenue

1.35B1.42B1.68B2.15B

Gross profit

1.22B1.28B1.53B1.94B

Operating income

401.30M399.91M552.90M793.66M

EBITDA

operating income before depreciation and amortisation

481.76M591.45M753.44M993.94M

Pretax income

423.86M530.45M697.48M937.26M

Net income

371.43M461.63M599.64M794.87M

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

362.81M444.92M594.69M798.87M

R&D

243.43M295.36M370.56M480.46M
Balance sheet, year end

Total assets

4.31B4.65B4.34B5.71B

Total liabilities

1.06B1.02B408.45M649.00M

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

3.26B3.63B3.93B5.06B

Total debt

629.35M606.17M16.17M15.04M

Cash and equivalents

2.53B3.16B3.10B4.51B

Net PP&E

fixed assets after depreciation

500.74M463.90M448.30M459.27M

Working capital

current assets less current liabilities

3.34B3.10B3.39B4.46B
Cash flow

Operating cash flow

394.07M438.95M529.76M964.11M

Capital expenditure

paid out, so below zero

-41.95M-51.06M-72.00M-70.03M

Depreciation and amortisation

49.54M51.60M55.05M56.23M

Free cash flow

operating cash flow plus capital expenditure

352.12M387.88M457.76M894.07M